Tags

Type your tag names separated by a space and hit enter

Reexamination of human T cell lymphotropic virus (HTLV-I/II) prevalence.
Proc Natl Acad Sci U S A. 1997 Jun 10; 94(12):6403-7.PN

Abstract

In the United States, blood donors are being screened for infection with human T cell lymphotropic viruses I and II (HTLV-I/II) by serologic means, which detect antibodies to the structural proteins of these viruses. Because patients with mycosis fungoides (MF) usually do not have such antibodies even though their cells harbor HTLV-I Tax and/or pol proviral sequences, it was questioned whether the prevalence of HTLV infection among healthy blood donors may also be underestimated by current means of testing. To examine this possibility, a study on specimens of relatives of mycosis fungoides patients (MFR) was begun. In addition, to collect data more expeditiously, a cohort of former injection drug users (IDUs) was tested by routine serologic methods, as well as by PCR/Southern blot analysis for Tax, pol, and gag proviral sequences and Western blot analysis for antibodies to the Tax gene product. To date, 6/8 MFRs and 42/81 (51.8%) of HIV-negative IDUs proved to be positive for HTLV, whereas routine serology identified none of the MFR and only 18/81 (22.2%) of the IDUs. Among the latter test subjects, the incidence of HTLV-I also proved to be 10 times higher than expected. Therefore, it is likely that among healthy blood donors infection with HTLV-I/II is more prevalent than is currently assumed. Since Tax is the transforming sequence of HTLV-I/II, testing for Tax sequences and antibodies to its gene product may be desirable in blood transfusion and tissue donor facilities.

Authors+Show Affiliations

Department of Medicine, New York University Medical Center, 550 First Avenue, New York, NY 10016, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9177230

Citation

Zucker-Franklin, D, et al. "Reexamination of Human T Cell Lymphotropic Virus (HTLV-I/II) Prevalence." Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 12, 1997, pp. 6403-7.
Zucker-Franklin D, Pancake BA, Marmor M, et al. Reexamination of human T cell lymphotropic virus (HTLV-I/II) prevalence. Proc Natl Acad Sci U S A. 1997;94(12):6403-7.
Zucker-Franklin, D., Pancake, B. A., Marmor, M., & Legler, P. M. (1997). Reexamination of human T cell lymphotropic virus (HTLV-I/II) prevalence. Proceedings of the National Academy of Sciences of the United States of America, 94(12), 6403-7.
Zucker-Franklin D, et al. Reexamination of Human T Cell Lymphotropic Virus (HTLV-I/II) Prevalence. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6403-7. PubMed PMID: 9177230.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reexamination of human T cell lymphotropic virus (HTLV-I/II) prevalence. AU - Zucker-Franklin,D, AU - Pancake,B A, AU - Marmor,M, AU - Legler,P M, PY - 1997/6/10/pubmed PY - 1997/6/10/medline PY - 1997/6/10/entrez SP - 6403 EP - 7 JF - Proceedings of the National Academy of Sciences of the United States of America JO - Proc Natl Acad Sci U S A VL - 94 IS - 12 N2 - In the United States, blood donors are being screened for infection with human T cell lymphotropic viruses I and II (HTLV-I/II) by serologic means, which detect antibodies to the structural proteins of these viruses. Because patients with mycosis fungoides (MF) usually do not have such antibodies even though their cells harbor HTLV-I Tax and/or pol proviral sequences, it was questioned whether the prevalence of HTLV infection among healthy blood donors may also be underestimated by current means of testing. To examine this possibility, a study on specimens of relatives of mycosis fungoides patients (MFR) was begun. In addition, to collect data more expeditiously, a cohort of former injection drug users (IDUs) was tested by routine serologic methods, as well as by PCR/Southern blot analysis for Tax, pol, and gag proviral sequences and Western blot analysis for antibodies to the Tax gene product. To date, 6/8 MFRs and 42/81 (51.8%) of HIV-negative IDUs proved to be positive for HTLV, whereas routine serology identified none of the MFR and only 18/81 (22.2%) of the IDUs. Among the latter test subjects, the incidence of HTLV-I also proved to be 10 times higher than expected. Therefore, it is likely that among healthy blood donors infection with HTLV-I/II is more prevalent than is currently assumed. Since Tax is the transforming sequence of HTLV-I/II, testing for Tax sequences and antibodies to its gene product may be desirable in blood transfusion and tissue donor facilities. SN - 0027-8424 UR - https://www.unboundmedicine.com/medline/citation/9177230/Reexamination_of_human_T_cell_lymphotropic_virus__HTLV_I/II__prevalence_ L2 - http://www.pnas.org/cgi/pmidlookup?view=long&pmid=9177230 DB - PRIME DP - Unbound Medicine ER -